Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 63

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Lower respiratory tract infection

Not recruiting

Study on the Safety and Immune Response of mRNA-1345 and mRNA-1365 for Infants with Acute Lower Respiratory Infection Aged 5 to 24 Months

Registered drug
Countries:LatviaLatvia
  • Participants:0–17 years · Healthy volunteers
  • Substances:MRNA-1345
  • Sponsor:Moderna Inc.

Influenza

Not recruiting

A Study of OVX836 Influenza Vaccine Given as Booster or Primary Vaccination in Healthy Adults Who Previously Received OVX836, Influenza Vaccine, or Placebo

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:INFLUENZA A (H1N1/WSN/1933) NUCLEOPROTEIN FUSED TO C-TERMINAL FRAGMENTS OF TWO AVIAN C4BP ALFA CHAIN SEQUENCES
  • Sponsor:OSIVAX Belgique

COVID-19

Not recruiting

Study on the Immune Response to Bretovameran COVID-19 mRNA Vaccine in Healthy Adults Aged 18-40

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Bretovameran
  • Sponsor:Universiteit Antwerpen

Influenza

Not recruiting

Study on the Best Time for Influenza Vaccine Administration in Adults Aged 60-85 Using Influenza Vaccine and Drug Combination

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type)
  • Sponsor:Rijksinstituut voor Volksgezondheid en Milieu (RIVM)

Influenza

Not recruiting

Study Comparing High-Dose vs. Standard-Dose Influenza Vaccine for Preventing Flu in Older Adults

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:Gentofte Hospital

COVID-19

Not recruiting

Study on the Safety and Immune Response of BIMERVAX as a COVID-19 Booster in Adolescents Aged 12 to 17 Years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · Healthy volunteers
  • Substances:SARS-COV-2 VIRUS, VARIANTS B.1.351-B.1.1.7, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HETERODIMER
  • Sponsor:Hipra Scientific S.L.

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

NSAID exacerbated respiratory disease

Not recruiting

Study on Aspirin's Role in Reducing COVID-19 Risk for Patients with Aspirin-Exacerbated Respiratory Disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Acetylsalicylic Acid
  • Sponsor:Uniwersytet Jagiellonski Collegium Medicum

Coronavirus infection

Not recruiting

Study on COVID-19 Prevention Using Sipavibart and Cilgavimab for Patients with Weakened Immune Systems

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Cilgavimab
  • Sponsor:AstraZeneca AB

Pulmonary arterial hypertension

Not recruiting

Study on Macitentan for Children with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years · Healthy volunteers
  • Substances:Macitentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

COVID-19

Not recruiting

Study on the Immune Response of COVID-19 Vaccine Tozinameran with Flu Vaccine Combinations in Adults Aged 65 and Over

Registered drug
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:Tozinameran
  • Sponsor:Cr2o B.V.

Pneumonia chlamydial+2

Not recruiting

Study on the Effects of Doxycycline for Preventing Antibiotic Resistance in Patients with Bacterial STDs (Chlamydia, Gonorrhea, Syphilis)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Doxycycline Monohydrate
  • Sponsor:Institute Of Tropical Medicine

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.